Key Drivers
- Cash cushion
- Ongoing burn
- Rich valuation
AIAI Summary
ZBIO has shifted from a survival-risk biotech to a milestone-risk story: its $718.5M cash runway through 2029 reduces near-term financing pressure, but the stock now depends almost entirely on timely FDA/regulatory execution and strong obexelimab data, with any slip likely to force a sharp valuation reset.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash cushion
- •Ongoing burn
- •Rich valuation
ZBIO has ample liquidity but remains deeply unprofitable and cash-burning, with rising leverage and a valuation that still looks stretched versus minimal revenue.
Price Behavior
Key Price Behavior Insights:
- •Lower-high pattern
- •Failed bounce
- •Key support zone
Over the last month, ZBIO has stayed in a clear downtrend with lower highs/lower lows, as a rebound toward $21.5–$21.8 stalled and the stock slipped back toward key support at $17.5–$18.2, leaving momentum weak and the RSI near neutral.
Sharp rebound from around $17.55 on 2026-04-29 into 2026-05-04, but it quickly faded
Sentiment & News
Key News Insights:
- •Regulatory on track
- •SLE expansion
- •ZB021 dosing
Zenas is advancing obexelimab toward 2026 FDA/EMA filings after strong IgG4-RD data, while also expanding its pipeline with early ZB021 and upcoming SLE readouts.
The updates are modestly positive for Zenas BioPharma, reinforcing confidence in obexelimab's near-term catalysts while adding longer-term pipeline optionality
Similar Companies in Healthcare
Other companies in the same sector with AI ratings